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and Acronyms
AAC = amino acid coding
ADR = adverse drug event(s)
cLQTS = congenital long QT
interval syndrome
diLQTS = drug-induced long
QT interval syndrome
EA = European-American
ESP = Exome Sequencing
Project
IKr = cardiac delayed rectiﬁer
potassium current
IKs = cardiac slow delayed
potassium rectiﬁer current
LQTS = long QT interval
syndrome
MAF = minor allele
frequency
QTc = corrected QT interval
SKAT = sequence kernel
association test
SNP = single nucleotide
polymorphism
TdP = torsades de pointes
VT = variable threshold
WES = whole exome
sequencing
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1431Long QT interval syndrome (LQTS) is a congenital or ac-
quired (usually drug-induced) change in ventricular repolari-
zation that can evoke the life-threatening ventricular
arrhythmia torsades de pointes (TdP) (1). Most drugs associ-
ated with drug-induced LQTS (diLQTS) have known
arrhythmogenic effects and are predominantly used in arrhythmia
therapy. However, nonantiarrhythmic drugs such as metha-
done, terfenadine, and haloperidol have also been associated
with diLQTS, and this has led to high-proﬁle restrictions and
withdrawals (2).
See page 1438
The diLQTS phenocopiesmany of the clinical features of the
congenital LQTS (cLQTS), which are caused by mutations in
genes encoding ion channels or their regulatory proteins (3).
In addition, ﬁrst-degree relatives of patients with diLQTS
have been reported to display exaggerated responses to
challenge with the QT interval–prolonging agent quinidine
(4). These observations, coupled with the widely held view
that adverse drug reactions (ADRs) include a genomic
component (5,6), have led to searches for DNA variants
predisposing to diLQTS (7–9). Mutations in cLQTS
disease genes have been reported in as many as 36% to
40% of diLQTS patients (10,11), consistent with the
notion that drug challenge may expose the congenital form
of the syndrome (12). In a recent study interrogating the
genetic predisposition to diLQTS using 1,424 tag single
nucleotide polymorphisms (SNPs) in 18 genes, the
KCNE1 missense polymorphism resulting in D85N
conferred an odds ratio of 9.0 for diLQTS (7). A genome-
wide association study has not identiﬁed strong associations
between common polymorphisms and diLQTS (13).
Whole-exome sequencing (WES) has led to the successful
discovery of an associated underlying genomic framework for
monogenic diseases including cLQTS (14). These approaches
have also been successfully applied to complex traits, for
example, in the identiﬁcation of variants in DCTN4-modi-
fying Pseudomonas infection susceptibility in patients with
cystic ﬁbrosis (15). In this study, we used WES to test the
hypothesis that rare variants predispose to diLQTS. We
report here the results of WES in 65 subjects in whom
diLQTS developed and 2 sets of control subjects: 148 drug-
exposed control subjects and 515 ethnically matched popu-
lation control subjects from the Exome Sequencing Project
(ESP) (16). We analyzed all amino acid coding (AAC) vari-
ants and also focused on genes in which mutations are known
to cause cLQTS or other arrhythmia syndromes.
Methods
Study cohort. DILQTS PATIENTS. Patients of self-reported
European-American (EA) ancestry were selected from a
cohort of patients seen at Vanderbilt University Medical Center
who presented with TdP or exaggerated QT interval prolonga-
tion (600 ms that decreased to <480 ms on drugdiscontinuation) secondary to
commonly prescribed drugs in-
cluding antiarrhythmic and anti-
psychotic drugs. In total, 67
patients met this deﬁnition (53
with TdP and 14 with exagger-
ated QT interval prolongation);
principal component analysis
conﬁrmed EA ancestry in 65 of
67 patients (Online Figs. 1 and 2)
(see the Online Appendix for de-
tails). Clinical data were extracted
manually from hospital charts by
physician review.
DRUG-EXPOSEDCONTROLSUBJECTS.
Drug-exposed control subjects
were identiﬁed from 845 adults
studied after initiation of QT in-
terval–prolonging antiarrhythmic
therapy. From this group (17),
we selected 148 Caucasian sub-
jects with a baseline corrected
QT interval (QTc) 470 ms, no
on-drug QTc interval >495 ms,
and maximal QTc interval change
<50 ms on drug.
ESP CONTROL SUBJECTS. We
selected 515 Caucasian subjects
determined to be unrelated by identity by descent from the
National Heart, Lung, and Blood Institute Grand Oppor-
tunity ESP to serve as a second set of control subjects (16).
The ESP control subjects were drawn from subjects with a
high body mass index, chronic obstructive pulmonary dis-
ease control, low low-density lipoprotein, and a set of deeply
phenotyped reference samples.
Whole-exome sequencing. The full methods on library
construction and preparation, exome capture, mapping and
variant calling, and quality control are described in the
Online Appendix.
Association testing. We performed unadjusted and
adjusted (age, sex, and ﬁrst and second principal compo-
nents) SNP-based association analyses using the Fisher exact
and exact logistic regression, respectively; a Bonferroni-
adjusted p value <6.39  107 was considered to be sta-
tistically signiﬁcant on a genome-wide level (78,204 AAC
variants [missense, nonsynonymous, or frameshift] were
identiﬁed, of which 59,977 [76.6%] had a minor allele fre-
quency [MAF] <5%).
We used unidirectional (variable threshold [VT]) (18) and
bidirectional (sequence kernel association test [SKAT]) (19)
rare variant aggregate approaches to test for gene-level as-
sociations between the diLQTS patients and the respective
control groups. A Bonferroni-adjusted p value <3.39 
106 was considered to be statistically signiﬁcant on a
genome-wide level for both VT and SKAT (14,746 genes
Table 1 Baseline Characteristics of Study Subjects
Patients Drug-Exposed Control Subjects*
N 65 148
Female 45 (69.2) 66 (44.6)
Age, yrs
Overall 58.9 (42.3–73.6) 65.7 (56.1–70.9)
Female 57.3 (42.3–72.6) 65.4 (58.9–73.3)
Male 61.2 (43.9–73.9) 60.7 (54.0–67.9)
Outcome
Torsades de pointes 51 (78.5) 0
QTc, ms 634 (602–667) 444 (427–462)
Index drugy
Quinidine 16 (24.6) d
Sotalol 15 (23.1) 132 (89.2)
Dofetilide 8 (12.3) 16 (10.8)
Amiodarone 7 (10.8) d
Procainamide 4 (6.2) d
Cardiac otherz 5 (7.7) d
Noncardiacx 19 (29.2) d
History
Hypertension 17 (26.2) 100 (67.6)
Diabetes 11 (17.9) 31 (21.0)
Ischemic heart
disease
20 (30.8) 42 (28.4)
Myocardial
infarction
17 (26.2) 37 (25.0)
Values are n (%) or median (interquartile range). *For drug-exposed control subjects, index drug
identiﬁes the drug with which they were challenged. ySeventeen patients had taken either 2
(n ¼ 16) or 3 (n ¼ 1) index drugs. zCardiac other includes encainide, mexiletine, lidocaine, bre-
tylium, and ibutilide. xNoncardiac includes hydroxyzine, nortriptyline, sertraline, escitalopram,
venlafaxine, trazadone, promethazine, methadone, triﬂuorperazine, prochlorperazine, tizanidine,
ﬂuoroquinolone, co-trimoxazole, sevoﬂurane, ﬂuconazole, levoﬂoxacin, metoclopramide, and clari-
thromycin.
QTc ¼ corrected QT interval.
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1432harbored an AAC variant) (see the Online Appendix for
details).
Given that our initial analysis approach is likely to be
underpowered (Online Figs. 3A and 3B), we used an
alternative analysis approach in which we selected the genes
with the strongest associations identiﬁed from both VT and
SKAT (p < 0.001) when comparing the diLQTS patients
and drug-exposed control group. We then attempted to
replicate those associations using the diLQTS patients
versus 515 population control subjects from the ESP using
both VT and SKAT aggregate analyses (p < 0.05); this use
of 2 control populations, 1 drug-exposed and 1 drawn from a
general population, is similar to those we previously used in a
candidate diLQTS analysis (7). We only considered genes to
be signiﬁcantly associated with diLQTS if they: 1) passed
the p < 0.001 cutoff in both types of rare variant analyses
(VT and SKAT) comparing diLQTS patients and drug-
exposed control subjects); and 2) replicated using the
diLQTS patients versus ESP population control subjects.
Candidate gene and gene-set analyses. A priori, we
selected a total of 20 genes with a strong level of evidence of
being associated with congenital arrhythmia syndromes
([cLQTSs: AKAP9, ANK2, CACNA1C, CAV3, KCNE1,
KCNE2, KCNH2, KCNJ2, KCNJ5, KCNQ1, SCN4B,
SCN5A, SNTA1; short QT interval syndrome: KCNQ1,
KCNH2, KCNJ2; Brugada syndrome: CACNA1C,
CACNB2, GPDL1, KCNE3, SCN1B, SCN3B, SCN5A;
catecholaminergic polymorphic ventricular tachycardia
(CPVT): CASQ2, RYR2) (Online Table 2). Previous studies
(8) implicated the D85N KCNE1 variant with diLQTS
(1.2% MAF in 4,300 EA subjects in the ESP); accordingly,
we included variants with an MAF <1.5% and deﬁned these
as rare. We calculated the proportions of diLQTS patients,
drug-exposed control subjects, and ESP control subjects
who harbored 1 or more rare variants in each of these genes
considered individually. The Fisher exact test was applied to
detect differences in rare variant burden between diLQTS
patients and drug-exposed control subjects (adjusted for
multiple comparisons [n ¼ 20], p < 0.0025 was considered
statistically signiﬁcant). For genes signiﬁcantly enriched
with rare variants among the diLQTS patients versus drug-
exposed control subjects, we proceeded to the diLQTS pa-
tients versus ESP control subjects comparison. Last, we
hypothesized that diLQTS patients are more burdened by
rare variants in the 3 well-deﬁned gene sets described pre-
viously consisting of the 20 congenital arrhythmia syndrome
genes, the subset of 13 cLQTS genes, and the subset of 7
cLQTS genes encoding potassium channel pore-forming
subunits or modulators (AKAP9, KCNE1, KCNE2,
KCNH2, KCNJ2, KCNJ5, KCNQ1). In these analyses, we
calculated the proportion of diLQTS patients, drug-exposed
control subjects, and ESP control subjects who harbored 1
or more rare variants in the genes listed earlier. A p
value <0.017 adjusted for multiple comparisons (n ¼ 3) was
considered statistically signiﬁcant. We selected genes that
passed p values adjusted for multiple comparisons whencomparing the diLQTS patients and the drug-exposed
control subjects and replicated these associations using the
ESP control subjects.
Statistical analyses. All analyses were performed using
PLINK/SEQ (http://atgu.mgh.harvard.edu/plinkseq/),
SAS version 9.2 (SAS Institute Inc., Cary, North Car-
olina), and R: A Language and Environment for statistical
Computing (http://R-project.org).
Ethics. Approval of the study of diLQTS and QT Star
Panel Study (QTSPS) subjects was obtained from the
Vanderbilt Institutional Review Board, and written
informed consent was obtained from each study participant
prior to enrollment. Each subject in the National Heart,
Lung, and Blood Institute Grand Opportunity ESP also
provided consent.Results
We analyzed DNA from 65 diLQTS patients and 148
drug-exposed control subjects of EA ancestry. Table 1 lists
the clinical characteristics of the diLQTS patients and the
drug-exposed control subjects, including the index drug
responsible for causing diLQTS. No summary level
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control subjects.
Association testing. INDIVIDUAL VARIANTS. Online Figure 4
depicts the QQ plot of the AAC single variant–based asso-
ciation analyses. Online Tables 4 and 5 present the strongest
associations for the single marker association analysis of AAC
variants in adjusted and unadjusted association models,
respectively. No single AAC variant reached the Bonferroni-
adjusted genome-wide signiﬁcance threshold (p < 6.39 
107). The KCNE1 D85N (rs1805128) variant conferred
odds ratios of 30.8 (p ¼ 0.0008) and 13.6 (p ¼ 0.019) for
inducing diLQTS in the unadjusted and adjusted association
analyses, respectively.
GENE-LEVEL ASSOCIATIONS. We identiﬁed rare AAC vari-
ants in a total of 14,746 genes. No gene reached the
Bonferroni-adjusted genome-wide signiﬁcance threshold
(p < 3.39  106). In the alternate rare variant gene-level
analyses approach, VT and SKAT identiﬁed 5 and 4
genes (7 different genes in total), respectively, that were
enriched with rare variants in the diLQTS patients versus
drug-exposed control subjects (p < 0.001). However, only 2
genes, ACN9 and KCNE1, were also identiﬁed in both VT
and SKAT at a signiﬁcance level of p < 0.05 using diLQTS
patients versus 515 ESP control subjects (Table 2).
The association in KCNE1 was driven by 2 rare missense
SNPs (D85N [rs1805128], n ¼ 6, and D76N [rs74315445],
n ¼ 1) present in 7 of the diLQTS patients (10.7%). By
contrast, only 1 missense variant (R98Q [rs150454912]) in
KCNE1 was identiﬁed among the drug-exposed control
subjects (0.7%), and 16 were identiﬁed among the ESP
control subjects (3.1%). KCNE1 D85N has previously been
implicated as a risk allele for diLQTS in a candidate gene
study of 176 subjects that included 27 of the 65 samples also
studied here (7). To ensure that our results were not driven
by overlapping samples from a previous study, we performed
subanalyses on the nonoverlapping 38 diLQTS patients
versus the 148 drug–exposed control subjects, which
conﬁrmed our initial ﬁndings (3 of 38 vs. 0 of 148, p ¼
0.008). In silico assessment of a rare variant function usingTable 2
Genes With Signiﬁcant Associations Between diLQTS
Patients and Drug-Exposed Control or ESP Control
Subjects According to Aggregated Rare Variant
Analysis
Gene
VT p Values SKAT p Values
diLQTS Patients
(N ¼ 65) vs.
Drug-Exposed
Control Subjects
(N ¼ 148)
diLQTS Patients
(N ¼ 65) vs. ESP
Control Subjects
(N ¼ 515)
diLQTS Patients
(N ¼ 65) vs.
Drug-Exposed
Control Subjects
(N ¼ 148)
diLQTS Patients
(N ¼ 65) vs. ESP
Control Subjects
(N ¼ 515)
KCNE1 0.0005 0.0033 0.0002 0.005
ACN9 0.0005 0.0006 0.0008 8.96105
Genes that reached a signiﬁcance level of p < 0.001 comparing the diLQTS patients and the drug-
exposed control subjects and also replicated using the diLQTS patients versus 515 ESP control
subjects (p < 0.05) using VT or SKAT.
diLQTS ¼ drug-induced long QT interval syndrome; ESP ¼ Exome Sequencing Project; SKAT ¼
sequence kernel association test; VT ¼ variable threshold.PolyPhen-2 and SIFT (sorting tolerant from intolerant)
suggests that the variants identiﬁed in KCNE1 (D85N,
D76N, and R98Q) are deleterious. Two rare heterozygous
missense SNPs in ACN9 (F53L [rs62624461] and T83I
[rs34146273]) drove the association for this gene; 9 diLQTS
patients were carriers of F53L and 1 was a carrier of T83I,
whereas 4 drug-exposed control subjects were carriers of
F53L. Based on data from the Encyclopedia of DNA Ele-
ments (ENCODE) consortium, the F53L variant is situated
in a region of high regulatory activity, whereas less regu-
latory activity was identiﬁed for the T83I variant (Online
Fig. 5). In addition, in silico assessment of a rare variant
function in ACN9 using PolyPhen-2 and SIFT indicates
that the F53L variant is more deleterious than the T83I
variant (Online Table 6). The F53L variant conferred odds
ratios of 8.5 and 6.0 for inducing diLQTS in adjusted and
unadjusted SNP-based association models, respectively
(p ¼ 0.001).
CANDIDATE GENE ANALYSES. We identiﬁed a 16- and 3.5-
fold enrichment among diLQTS patients harboring a rare
AAC variant in KCNE1 compared with the drug-exposed
control and ESP control subjects (p ¼ 0.001 and 0.009,
respectively). No other individual congenital arrhythmia
gene displayed statistically signiﬁcant enrichment among the
diLQTS patients compared with the drug-exposed control
subjects (Table 3).
We also examined the proportion of patients who
harbored 1 or more rare variants in pre-deﬁned gene sets.
Patients with diLQTS had an approximately 2-fold en-
richment of rare AAC variants in potassium channel or
channel-modulating protein-encoding genes compared with
the drug-exposed and ESP control subjects (p ¼ 0.009 and
p ¼ 0.013, respectively) (Table 3). To evaluate whether this
association was independent of KCNE1, we performed a
subset analysis of potassium channel pore-forming subunits
or modulatory proteins, but excluding KCNE1, which
conﬁrmed our initial ﬁndings compared with drug-exposed
control and the ESP control subjects (p ¼ 0.032 and
0.009, respectively). No enrichment of rare AAC variants
among diLQTS patients was seen in other gene-set tests of
congenital arrhythmia genes or cLQTS genes (Table 3).Discussion
In the present study, we used WES to test the hypothesis
that rare variants are associated with the risk of the devel-
opment diLQTS. Using rare variant aggregation ap-
proaches, variants in 7 genes were associated with diLQTS
susceptibility. However, only 2 genes, KCNE1 and ACN9,
were consistently associated with diLQTS across different
aggregate analyses with different control populations. We
also found a greater burden of AAC variants in cLQTS
potassium channel or modulating protein-encoding genes
among diLQTS patients compared with drug-exposed and
ESP control subjects.
Table 3
Proportion of Subjects Harboring 1 or More Rare Amino Acid Changing Variants (Minor Allele Frequency <1.5% in
ESP4300 EA) in 20 High-Priority Genes
Gene
diLQTS
Patients
(N ¼ 65)
Drug-Exposed
Control Subjects
(N ¼ 148)
Proportional
Enrichment
(diLQTS Patients/
Drug-Exposed
Control Subjects) p Value
ESP Control
Subjects
(N ¼ 515)
Proportional
Enrichment
(diLQTS Patients/
ESP Control Subjects)
Replication
p Value
AKAP9* 18 (27.7) 20 (13.5) 2.0 0.019 84 (16.3) 1.7
ANK2* 9 (13.8) 14 (10.1) 1.5 0.346 62 (12.0) 1.2
CACNA1C* 1 (1.5) 7 (0.3) 0.3 0.440 27 (5.2) 0.3
CACNB2* 0 (0.0) 1 (0.0) 0.0 1.000 5 (1.0) 0.0
CAV3* 1 (1.5) 0 (0.0) d 0.305 6 (1.2) 1.3
GPD1L* 2 (3.1) 1 (0.7) 4.6 0.221 4 (0.8) 4.0
KCNE1* 7 (10.8) 1 (0.7) 15.9 0.001 16 (3.1) 3.5 0.009
KCNE2* 2 (3.1) 4 (2.7) 1.1 1.000 10 (1.9) 1.6
KCNE3* 0 (0.0) 3 (2.0) 0.0 0.555 9 (1.7) 0.0
KCNH2* 4 (6.2) 3 (2.0) 3.0 0.204 9 (1.7) 3.5
KCNQ1* 1 (1.5) 1 (0.7) 2.3 0.518 4 (0.8) 2.0
RYR2* 3 (4.6) 14 (9.5) 0.5 0.283 35 (6.8) 0.7
SCN1B* 0 (0.0) 4 (2.7) 0.0 0.316 13 (2.5) 0.0
SCN4B* 0 (0.0) 2 (1.4) 0.0 1.000 0 (0.0) 0.0
SCN5A* 2 (3.1) 10 (6.8) 0.5 0.353 27 (5.2) 0.6
SNTA1* 1 (1.5) 1 (0.7) 2.3 0.518 6 (1.2) 1.3
Collapsedy
Congenital arrhythmia genesz 33 (49.2) 67 (45.9) 1.1 0.55 251 (48.7) 1.0
cLQTS genesx 30 (44.6) 51 (34.5) 1.3 0.126 203 (39.4) 1.2
Potassium channel cLQTS genesjj 24 (36.9) 28 (18.9) 2.0 0.009 114 (22.1) 1.7 0.013
Values are n (%). Four genes with no rare amino acid changing variants (minor allele frequency <1.5% among 4,300 European Americans in the ESP [ESP4300 EA]) in diLQTS patients and drug-exposed
control subjects are not listed (CASQ2, KCNJ2, KCNJ5, SCN3B). Congenital arrhythmia genes include genes with strong evidence of being associated with congenital long QT interval syndrome, Brugada
syndrome, catecholaminergic polymorphic ventricular tachycardia, and short QT interval syndrome. *Adjusted for multiple comparisons (n ¼ 20); p < 0.0025 is considered statistically signiﬁcant. yAdjusted
for multiple comparisons (n ¼ 3); p < 0.017 is considered statistically signiﬁcant. zAKAP9, ANK2, CACNB2, CACNA1C, CASQ2, CAV3, GPD1L, KCNE1, KCNE2, KCNE3, KCNH2, KCNJ2, KCNJ5, KCNQ1, SCN1B,
SCN3B, SCN4B, SCN5A, RYR2, SNTA1. xAKAP9, ANK2, CACNA1C, CAV3, KCNE1, KCNE2, KCNH2, KCNJ2, KCNJ5, KCNQ1, SCN4B, SCN5A, SNTA1. jjKCNE1, KCNE2, KCNH2, KCNJ2, KCNJ5, KCNQ1, AKAP.
cLQTS ¼ congenital long QT interval syndrome; other abbreviations as in Table 2.
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1434We found that rare AAC variation in genes encoding
potassium channel modulators were associated with
diLQTS. A common action of most drugs associated with
diLQTS is to inhibit the rapid component of the cardiac
delayed rectiﬁer potassium current (IKr), encoded by
KCNH2 (3,7). Net drug effects on repolarization are
thought to be mediated by direct repolarizing/prolonging
effects in IKr (or perhaps other currents) (20), as well as by
effects on other currents ﬂowing during repolarization; thus,
for example, marked QT interval prolongation seems to be
less of a liability with IKr blockers that also inhibit inward
sodium or calcium currents (e.g., verapamil, amiodarone).
Hence, the extent to which an IKr-blocking drug causes
diLQTS may reﬂect both the extent of IKr block itself as well
as the interplay of multiple depolarizing and repolarizing ion
currents; the concept that multiple ionic currents ordinarily
provide a buffer against excessive QT interval prolongation
has been termed repolarization reserve (12). This concept
further suggests that multiple genetic or acquired lesions in
these currents may remain asymptomatic until an IKr-
blocking drug exposes them, a situation of reduced repo-
larization reserve. In particular, multiple studies have
implicated the reduction of function in cardiac slow delayed
potassium rectiﬁer current (IKs), another important repola-
rizing current, as an important contributor to reducedrepolarization reserve (21). This represents a speciﬁc
example of the more general “2-hit” hypothesis in which the
combination of a genetic variant impairing IKs and addi-
tional risk factors (in the diLQTS patients, a selective IKr
blocker) increases the risk of diLQTS.
Using an agnostic rare variant approach, we identiﬁed
2 genes associated with diLQTS: KCNE1 and ACN9
(Table 2). KCNE1 was previously associated with T-wave
morphology, QT interval, and the LQT5 form of cLQTS
(7,22,23). Indeed, 1 previous study in a Japanese cohort
implicated the D85N variant as a cause of the cLQTS,
although its frequency in our control populations suggests
that it is unlikely to provoke the full-blown congenital
LQTS in the absence of other QT interval–prolonging in-
ﬂuences such as other genetic variants and drugs (24).
KCNE1 encodes a transmembrane protein whose co-
assembly with the product of KCNQ1 is required to reca-
pitulate IKs (25). Highlighting the importance of KCNE1
in the setting of diLQTS was the proportion of diLQTS
patients burdened by rare AAC variants in KCNE1
compared with both control groups (11% [7 of 65] vs. 2.5%
8 [17 of 663], respectively; p ¼ 0.0039). The ability to
identify KCNE1 with the methods applied in the present
study lends support to the notion of reduced repolarization
reserve via decreased IKs being critical for the predisposition
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also replicate here the D85N signal that we and others
previously reported in a large candidate gene study evalu-
ating the risk of diLQTS; this ﬁnding thus further reinforces
the status of D85N as a risk allele in this setting and suggests
that studies be performed to determine whether avoiding
QT interval–prolonging drugs in patients known to carry
this variant reduces diLQTS. By comparison, little is known
about the human homolog of ACN9 and how it may
contribute to diLQTS. ACN9 is believed to be involved in
gluconeogenesis (26) and is required for the assimilation of
ethanol or acetate into carbohydrate and has also been
identiﬁed as a correlate of alcohol dependence (27).
Although functional studies are paramount to truly deter-
mine the suggested link between ACN9 and diLQTS, but
are beyond the scope of the present paper, it is noteworthy
that the greatest driver in the ACN9 signal (F53L) is in a
region of considerable regulatory activity, which could be
important in the setting of diLQTS. In comparison, little
regulatory activity is identiﬁed in the vicinity of T83I.
Among the 65 diLQTS patients, 2 variants drove the
KCNE1 association, D76N and D85N, and D76N has
previously been associated with the congenital form of the
syndrome. However, although D85N has previously been
associated with diLQTS, D76N has not (7). The D76N
variant is a known suppressor of currents KvLQT1 and
HERG (encoded by KCNQ1 and KCNH2, respectively) and
was 1 of 4 rare KCNE1 variants characterized by Bianchi
et al. (28), 3 of which were functionally important. The
enrichment of rare variants among patients with LQTS (29)
and among diLQTS patients (30) compared with healthy
subjects supports the notion of diLQTS being a cLQTS
phenocopy via pharmacologically or genetically mediated
perturbations of cardiac repolarization.
Although previous studies have identiﬁed single loci or
SNPs strongly predictive of some ADRs (5,6), this does not
appear to be the case with diLQTS. Our data support the
idea that the fundamental lesion leading to diLQTS sus-
ceptibility is initially subclinical changes in the physiology of
cardiac repolarization and that this can arise from rare ge-
netic variation in multiple components of that system and is
not restricted to a single SNP or gene (i.e., genetic variation
in clusters of genes can give rise to the same phenotype) (31).
In keeping with such a systems approach, we examined rare
AAC variants in 3 well-deﬁned gene sets/networks (32).
Although we did not see a greater burden of rare variants
among diLQTS patients in 2 of the 3 gene sets, 37% (24 of
65) of patients with diLQTS harbored 1 or more rare AAC
variants in cLQTS potassium genes and their modulators
compared with 21% (142/663) in the control groups, rein-
forcing the importance of viewing disease phenotypes in the
context of a systems approach; importantly, this enrichment
was observed even when KCNE1 was omitted from the
analysis.
Although an enrichment of rare AAC variants in cLQTS
potassium channel pore-forming or modulator genes wasidentiﬁed among diLQTS patients, the majority of diLQTS
patients (w63%) were not burdened by rare AAC variants
in these genes, suggesting that other mechanisms outside the
coding regions of cLQTS-associated potassium channels
affect diLQTS susceptibility. In support of this idea, several
studies have implicated noncoding variants in NOS1AP and
in KCNQ1 as modulators of penetrance in cLQTS (33,34)
and in amiodarone-related diLQTS (35). Among diLQTS
patients, the cLQTS gene harboring the greatest proportion
of rare AAC variants was AKAP9, encoding a KCNQ1
partner required to transduce beta-adrenergic receptor acti-
vation of IKs (36). A mutation in AKAP9 in the KCNQ1
binding domain reduces the interaction between KCNQ1
and AKAP9, blunting a physiological adrenergic-mediated
increase in IKs, thereby generating the LQT11 phenotype
(37).
Recent ﬁndings by Crotti et al. (14) identiﬁed rare de
novo variants in genes encoding calmodulin (CALM1 and
CALM2) associated with LQTS and recurrent cardiac ar-
rests. Among the diLQTS patients and the drug-exposed
control subjects, no rare AAC variants in the 3 calmodulin
genes were identiﬁed.
Study limitations. One limitation of the present study re-
lates to the rarity of the phenotype in question, which
translates into a small case group and thus limited study
power (Online Figs. 3A and 3B). Although a single variant
association testing approach may prove useful in the setting
of common variants, it performs less well in a rare variant
setting (e.g., MAF ¼ 1% to 2%), although effect sizes and
associated MAF are estimates of the true values.
In comparison, gene-collapsing tests performed better,
although limited study power remains an issue. In addition,
to limit effects associated with population stratiﬁcation that
may lead to spurious associations, we only included pop-
ulations of the same ancestry, which reduced the sample size
even further and limits the extent to which our ﬁndings can
be applied to other ancestries. Another limitation relates to
the lack of phenotypic information for the ESP control
subjects, which may have affected our ﬁndings. However, as
diLQTS/TdP is a rare ADR, the effects of this ascertain-
ment bias in our study ﬁndings are likely to be small.
Although a large, well-phenotyped reference population
with individual level information would provide a better
comparison, such large, publicly available datasets are not yet
available. We adopted the approach of dual comparisons,
patients versus drug-exposed control subjects and patients
versus population control subjects, to mitigate this issue.
Other limitations that warrant consideration include the
distribution of causative alleles throughout the genome (i.e.,
not conﬁned to single genes) may also have affected our
ﬁndings. Thus, a traditional single marker association
approach was unsuccessful for implicating disease loci
related to diLQTS. By contrast, aggregated rare variant
analyses, an emerging standard in rare variant analyses of
complex disease, identiﬁed 2 genes, 1 of which has a clear
biological signiﬁcance associated with diLQTS. Although
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functional characterization of each variant would be a useful
approach to help establish such causation, including ACN9.
Although diLQTS patients were signiﬁcantly more
burdened by rare AAC variants in potassium channel
cLQTS genes compared with the drug-exposed control and
the ESP control subjects (36.9% vs. 18.9% and 22.1%,
respectively), we acknowledge the possibility that the direct
genetic effect induced by rare AAC variants in potassium
channel cLQTS genes may be small, considering that
w20% of controls also carried a rare AAC variant in these
genes. However, based on ﬁndings from previous case-
control studies, a 2-fold (or greater) enrichment among
diLQTS-affected patients compared with unaffected sub-
jects does lend support to the identiﬁed 2-fold times
enrichment of rare AAC variants in potassium channel
cLQTS genes (7,24). In agreement with the current state of
practice, we used multiple tests assuming uni- and bidirec-
tional effects (34). However, a lack of independence among
such variant aggregate tests represents a limitation.Conclusions
Using next-generation sequencing, we identiﬁed rare vari-
ants in KCNE1 (D76N and D85N) and ACN9 associated
with diLQTS. Furthermore, our ﬁndings suggest that
variation in potassium currents may contribute to the
phenotype, because diLQTS patients had a greater burden
of AAC variants than the control subjects. The present
study not only provides insights into the underlying genetic
architecture predisposing to diLQTS, but also lends support
to the notion that that multiple rare variants, notably across
cLQTS genes, predispose to diLQTS.
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